KORILIP NEO

General characteristics. Structure:

Active agents: Cocarboxylasi hydrochloridum – 12,5 mg, Riboflavinum – 1,0 mg, lipoic acid (thioctic acid) – 6,0 mg;
Excipients: fat firm (fatty acids glycerides).

Description. Suppositories of yellow color, a torpedo-shaped form with possible impregnations of orange-yellow color.

Pharmacological properties:

The combined drug which effect is defined by effects, the vitamins and coenzymes which are its part, and also their synergistic action.
Cocarboxylasi hydrochloridum (coenzyme) catalyzes a carboxylation and decarboxylation of A-ketonic acids, participates in processes of carbohydrate metabolism. Through participation in a pentozny cycle indirectly regulates synthesis of nucleic acids, proteins, lipids. Promotes correction of a metabolic acidosis and a cellular hypoxia, and also other disbolism (insufficiency of function of a liver, kidneys, cardiovascular system, chronic intoxications).
Riboflavinum (B2 vitamin) as a coenzyme of flavinprotein participates in regulation of redoxreactions (in processes carbohydrate, proteinaceous and a lipometabolism). Plays an important role in synthesis of hemoglobin and in maintenance of normal visual function of an eye, a condition of mucous membranes and skin.
Lipoic acid participates in oxidizing decarboxylation of pyruvic acid and A-ketonic acids, in regulation of lipidic and carbohydrate metabolism, plays an important role in the course of formation of energy in an organism. Lipoic acid possesses hepatoprotective action, improves disintoxication function of a liver, protects from influence ekzo-and endotoxins.
Korilip improves fabric exchange at various physiological and morbid conditions needing correction by cofactors and substrates.

Indications to use:

Drug is shown to use with the preventive and medical purpose in complex therapy at various morbid conditions at children, such as:

• chronic fabric hypoxia,
• decrease in immunity,
• bacterial and viral infections, including acute intestinal infections
• chronic somatopathies,
• chronic intoxications.
• disturbance of food (hypotrophy) at children.

Route of administration and doses:

Drug is used rektalno. Having exempted from packaging, to enter suppository into an anus after preliminary bowel emptying.
Suppositories are appointed to children till 1 year on 1 suppository a day.
Duration of a course of treatment – 10 days. The general duration of treatment – 3-4 courses with an interval in 20 days (3 – 4 months).

Features of use:

Criteria of duration of treatment along with a clinical state are cytochemical indicators of activity of enzymes of leukocytes of peripheral blood (a succinatedehydrogenase and a glitserofosfatdegidroginaza).

Interaction with other medicines:

Negative interaction was not noted. Drug can be used at complex therapy.

Contraindications:

Reaction of hypersensitivity to the components which are a part of drug.
Inflammation or bleeding in a rectum (the contraindication connected with way of introduction).

Storage conditions:

In the place protected from light at a temperature not above 20 °C. To store in the place, unavailable to children.

Period of validity 2 years. Not to use after the termination of the period of validity specified on packaging.

Issue conditions:

According to the recipe

Packaging:

Suppositories rectal (12,5 mg + 1 mg + 6 mg). On 5 suppositories in a blister strip packaging from a film polyvinyl chloride. Two planimetric packagings together with the application instruction in a pack cardboard.